Conatus Pharmaceuticals Adds $7.5M

San Diego-based Conatus Pharmaceuticals, a biopharmaceuticals firm working on treatments for hepatitis C, said this week that it has closed on an additional $7.5M in its Series B funding round. The round came from MPM Capital. The new funding brings the total raised in the round to $32.5M. As part of the funding, MPM's Jim Scopa joins the company's board. The firm said the funds will go toward clinical development of its CTS-1027 drug candidate. More information »